Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 21, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-09-06
DOI
10.1186/s12933-022-01585-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
- (2022) Tahmineh Kandelouei et al. MEDIATORS OF INFLAMMATION
- Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial
- (2021) Ehtasham Ahmad et al. DIABETES OBESITY & METABOLISM
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating GLP-1 Levels as a Potential Indicator of Metabolic Syndrome Risk in Adult Women
- (2021) Min Joo Seon et al. Nutrients
- Glucagon‐like peptide‐1 receptor agonists improve biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomised controlled trials
- (2021) Jonathan J. H. Bray et al. DIABETES OBESITY & METABOLISM
- Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme
- (2020) Tina K. Thethi et al. DIABETES OBESITY & METABOLISM
- Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
- (2020) Niki Katsiki et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 trials
- (2019) V. R Aroda et al. DIABETES & METABOLISM
- Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial
- (2019) Bernard Zinman et al. Lancet Diabetes & Endocrinology
- Cardiovascular Disease in Type 2 Diabetes: A Review of Sex-Related Differences in Predisposition and Prevention
- (2019) Abdallah Al-Salameh et al. MAYO CLINIC PROCEEDINGS
- Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
- (2019) Philip Newsome et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
- (2019) Vanita R. Aroda et al. DIABETES CARE
- Liraglutide attenuates pre-established atherosclerosis in apolipoprotein E deficient mice via regulation of immune cell phenotypes and pro-inflammatory mediators
- (2019) Robyn Bruen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial
- (2019) Ofri Mosenzon et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg as add-on to 1–3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)
- (2019) M.S. Capehorn et al. DIABETES & METABOLISM
- Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial
- (2019) Helena W. Rodbard et al. DIABETES CARE
- Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial
- (2019) Ildiko Lingvay et al. Lancet Diabetes & Endocrinology
- Cardiovascular biomarkers in clinical studies of type 2 diabetes
- (2018) Maria P. A. Baldassarre et al. DIABETES OBESITY & METABOLISM
- Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
- (2018) Helena W Rodbard et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials
- (2017) Mohsen Mazidi et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
- (2017) Bo Ahrén et al. Lancet Diabetes & Endocrinology
- Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial
- (2017) Vanita R Aroda et al. Lancet Diabetes & Endocrinology
- GLP-1 Induces Barrier Protective Expression in Brunnerʼs Glands and Regulates Colonic Inflammation
- (2016) Claus H. Bang-Berthelsen et al. INFLAMMATORY BOWEL DISEASES
- A Test in Context
- (2016) Paul M Ridker JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Longitudinal association of C-reactive protein and Haemoglobin A1c over 13 years: the European Prospective Investigation into Cancer - Norfolk study
- (2015) Sara Ahmadi-Abhari et al. Cardiovascular Diabetology
- GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R
- (2015) Bernardo Yusta et al. DIABETES
- Association of C-Reactive Protein With Cardiovascular Disease Mortality According to Diabetes Status: Pooled analyses of 25,979 participants from four U.K. prospective cohort studies
- (2011) A. P. Kengne et al. DIABETES CARE
- The Inflammasome in Atherosclerosis and Type 2 Diabetes
- (2011) S. L. Masters et al. Science Translational Medicine
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
- (2008) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease
- (2008) Jeppe Zacho et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started